Study 2 of 11 for search of: "Paresthesia"
Previous Study Return to Search Results Next Study

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Safety of Two Epidural Catheters in Thoracic Epidural Anaesthesia (TEA)
This study has been completed.
Sponsors and Collaborators: Maastricht University Medical Center
B. Braun Melsungen AG
Information provided by: Maastricht University Medical Center
ClinicalTrials.gov Identifier: NCT00394459
  Purpose

Primary Objective: The primary objective is to demonstrate that the safety of Perifix New is non-inferior to using Perifix Standard when applied for thoracic epidural anaesthesia.

Primary Endpoint: Incidence of spontaneous paraesthesia during catheter insertion

Secondary Objectives: The secondary objectives are to determine the safety and performance of the investigational product: frequency of inadvertent vascular cannulation, difficulties involved in insertion and removal of the catheter, other safety features and data for the evaluation of handling characteristics.

Title: Randomised, prospective, single-blind, controlled, multicenter study on the safety of two epidural catheters in patients undergoing surgery under thoracic epidural anaesthesia

Investigational Product: Perifix Epidural Anaesthesia Catheter

Test Product: Perifix New

Reference Product: Perifix Standard

Number of Sites and Countries: 2 sites in The Netherlands

Indication: Thoracic epidural anaesthesia

Study Design: Randomised, prospective, single-blind, controlled study in 2 study centers, phase IV

Perifix New and Perifix Standard meet all the appropriate provisions of the relevant legislation implementing European Directives (both have CE-marking).

Study Duration: 2 year duration

Study Start: March-April 2005

Sample Size: n = 2*70 patients


Condition Intervention Phase
Anesthesia, Epidural
Paraesthesia
Device: Perifix Epidural Anaesthesia Catheter
Device: Perifix Standard
Device: Perifix New
Phase IV

MedlinePlus related topics: Anesthesia
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Single Blind (Subject), Active Control, Parallel Assignment, Safety Study
Official Title: Randomised, Prospective, Single-Blind, Controlled Multicenter Study on the Safety of Two Epidural Catheters in Patients Undergoing Surgery Under Thoracic Epidural Anaesthesia

Further study details as provided by Maastricht University Medical Center:

Primary Outcome Measures:
  • The primary end-point will be the incidence of spontaneous paraesthesia during catheter insertion in TEA-patients. [ Time Frame: 1 hour ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • The frequency of inadvertent vascular cannulation [ Time Frame: 1 hour ] [ Designated as safety issue: Yes ]
  • Difficulties involved in insertion and removal of the catheter [ Time Frame: 1 week ] [ Designated as safety issue: Yes ]
  • Data on additional complications [ Time Frame: 1 week ] [ Designated as safety issue: Yes ]
  • Data for the evaluation of handling characteristics [ Time Frame: 1 week ] [ Designated as safety issue: No ]

Enrollment: 140
Study Start Date: April 2005
Study Completion Date: December 2007
Arms Assigned Interventions
A: Active Comparator
Perifix Standard
Device: Perifix Epidural Anaesthesia Catheter
Epidural Catheter
Device: Perifix Standard
B: Experimental
Perifix New
Device: Perifix Epidural Anaesthesia Catheter
Epidural Catheter
Device: Perifix New

Detailed Description:

Epidural anaesthesia is a central neuraxial block technique with many applications. Improvements in equipment, drugs and technique have made it a popular and versatile anaesthetic technique, with applications in surgery, obstetrics and pain control. Both single injection and catheter techniques can be used. Its versatility means it can be used as an anaesthetic, as an analgesic adjuvant to general anaesthesia, and for postoperative analgesia in procedures involving the lower limbs, perineum, pelvis, abdomen and thorax.

Although epidural anaesthesia is a safe technique, during the insertion of epidural catheters several side effects may occur, including transient paraesthesia and inadvertent vascular cannulation.

Reported incidences for paraesthesia vary widely between about 0.2% and 50% in different articles, depending on the catheter (catheter material, soft-tipped or firm-tipped catheter), the applied technique (lumbar or thoracic epidural anaesthesia, depth of catheter insertion), the approach (midline or paramedian) and the included patients (obstetrical or non-obstetrical). Paraesthesias are not supposed to lead to permanent neurological sequelae, but are unpleasant and perturbing sensations for the patient.

Besides inadvertent intrathecal location of the catheter, further problems include technical difficulties during threading or removal of the catheter. Here, the catheter shaft material seems to be the crucial factor for the incidence of problems.

Based upon years of experience, a wide range of epidural catheters were created, among them the Perifix catheter of B. Braun. Common features are their high tensile strength and stretch resistance, excellent shaft stability with easy visualisation of blood or spinal fluid due to the crystal clear material, no risk of forming loops or knots, and softening of catheter within a few hours due to water absorption of the polyamide material.

Recently, B. Braun Melsungen AG has developed a new generation of Perifix epidural catheters, which are already CE-labeled. These new catheters are different in their composition compared to the current Perifix Standard catheter with regard to the catheter material and tip configuration. They have an outer poly-urethane liner and an inner polyamide body. Experimental tests have shown that the positive features (e.g. pushability, kink resistance, gliding, withdrawal) of the Perifix Standard catheter can be maintained. Due to the polyurethane outer layer, the catheter gets softer when reaching body temperature immediately upon insertion. Based on this, it is expected that paraesthesias during catheter injection can be reduced by at least 20%.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients scheduled for thoracic epidural anaesthesia (TEA), with or without general anaesthesia.
  • American Society of Anesthesiologists (ASA) class I-III
  • Patients aged 18 and ≤ 75 years of age

Exclusion Criteria:

  • Anamnestic exclusion criteria are all contraindications for epidural anaesthesia.
  • Severe scoliosis, previous surgery on the spine, M. Bechterew disease
  • Non-competent and non-cooperative patients
  • Patients with medicament and drug abuse problems, problems in communication, participating in parallel in another clinical study with experimental drugs or devices, receiving prohibited concomitant therapies
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00394459

Locations
Netherlands
University Hospital Maastricht
Maastricht, Netherlands, 6202 AZ
University Hospital Utrecht
Utrecht, Netherlands, 3584 CX
Sponsors and Collaborators
Maastricht University Medical Center
B. Braun Melsungen AG
Investigators
Study Chair: Mathieu Gielen, MD, PhD Radboud UMC NIjmegen
Principal Investigator: Marco Marcus, MD, PhD Maastricht University Medical Center
  More Information

Study ID Numbers: H-04-078-04
Study First Received: October 31, 2006
Last Updated: December 19, 2007
ClinicalTrials.gov Identifier: NCT00394459  
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Maastricht University Medical Center:
Anaesthetic techniques
epidural
catheters
paraesthesia
side effects
Anesthesia, Epidural [E03.155.086.131]

Study placed in the following topic categories:
Signs and Symptoms
Sensation Disorders
Somatosensory Disorders
Paresthesia
Neurologic Manifestations

Additional relevant MeSH terms:
Nervous System Diseases

ClinicalTrials.gov processed this record on January 16, 2009